A Research Study to Assess if CC-930 is Safe in Treating Subjects With Discoid Lupus Erythematosus
Public ClinicalTrials.gov record NCT01466725. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Pilot, Multicenter, Randomized, Placebo-Controlled Sequential, Ascending Dose Study to Characterize the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Activity of CC-930 in Subjects With Recalcitrant Discoid Lupus Erythematosus (DLE)
Study identification
- NCT ID
- NCT01466725
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Celgene
- Industry
- Enrollment
- 5 participants
Conditions and interventions
Conditions
Interventions
- CC-930 Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 64 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 31, 2011
- Primary completion
- Jul 29, 2012
- Completion
- Jul 29, 2012
- Last update posted
- Nov 18, 2019
2011 – 2012
United States locations
- U.S. sites
- 19
- U.S. states
- 14
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UAB Dermatology | Birmingham | Alabama | 35233 | — |
| The Regents of the University of California | Irvine | California | 92697 | — |
| Medical Faculty Associates | Washington D.C. | District of Columbia | 20037 | — |
| Advanced Pharma, CR, LLC | Miami | Florida | 33136 | — |
| University of Miami - Department of Dermatology | Miami | Florida | 33136 | — |
| Rush Medical Center | Chicago | Illinois | 60612 | — |
| North Shore University Health System | Skokie | Illinois | 60077 | — |
| SIU School of Medicine | Springfield | Illinois | 62702 | — |
| Tulane University School of Medicine | New Orleans | Louisiana | 70112 | — |
| John Hopkins University | Baltimore | Maryland | 21205 | — |
| Boston Cancer Center | Boston | Massachusetts | 02118 | — |
| University of Minnesota-Department of Dermatology | Minneapolis | Minnesota | 55455 | — |
| University of Rochester Medical Center | Rochester | New York | 14623 | — |
| Ohio State Univ Medical Center, Division of Dermatology | Columbus | Ohio | 43221 | — |
| Rhode Island Hospital University Dermatology, Inc. | Providence | Rhode Island | 02903 | — |
| Medical University of South Carolina | Charleston | South Carolina | 29425 | — |
| Dermatology and Research | Dallas | Texas | 75230 | — |
| University of Texas Dermatology | Houston | Texas | 77030 | — |
| Sun Research Institute | San Antonio | Texas | 78215 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01466725, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 18, 2019 · Synced May 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01466725 live on ClinicalTrials.gov.